Categories
Uncategorized

Alzheimer’s Drug Targets People With Mild Cognitive Impairment. What Does That Mean?

The approval of a controversial new drug for Alzheimer’s disease, Aduhelm, is shining a spotlight on mild cognitive impairment — problems with memory, attention, language or other cognitive tasks that exceed changes expected with normal aging. After initially indicating that Aduhelm could be prescribed to anyone with dementia, the Food and Drug Administration now specifies […]

Categories
Uncategorized

Facing Headwinds on New Alzheimer’s Drug, Biogen Launches Controversial Campaign

Do you sometimes lose your train of thought or feel a bit more anxious than is typical for you? Those are two of the six questions in a quiz on a website co-sponsored by the makers of Aduhelm, a controversial new Alzheimer’s drug. But even when all responses to the frequency of those experiences are […]

Categories
Uncategorized

KHN’s ‘What the Health?’: Here Comes Reconciliation

Can’t see the audio player? Click here to listen on SoundCloud. You can also listen on Spotify, Apple Podcasts, Stitcher, Pocket Casts or wherever you listen to podcasts. The expansion of health benefits is a major piece of the tentative budget deal reached this week by Democrats in Congress. They plan to press ahead — […]

Categories
Uncategorized

Why We May Never Know Whether the $56,000-a-Year Alzheimer’s Drug Actually Works

The Food and Drug Administration’s approval in June of a drug purporting to slow the progression of Alzheimer’s disease was widely celebrated, but it also touched off alarms. There were worries in the scientific community about the drug’s mixed results in studies — the FDA’s own expert advisory panel was nearly unanimous in opposing its […]

Categories
Uncategorized

Doctores sopesan pros y contras de recetar la nueva droga para el Alzheimer

Mientras médicos y expertos en políticas de salud debaten los méritos de Aduhelm, el primer fármaco para el Alzheimer aprobado en 18 años, los pacientes simplemente quieren saber: “¿me ayudará?”. Los médicos no tienen una respuesta definitiva. “En cada persona, será absolutamente imposible de predecir”, dijo el doctor Allan Levey, director del Centro de Investigación […]

Categories
Uncategorized

KHN’s ‘What the Health?’: Un-Trumping the ACA

Can’t see the audio player? Click here to listen on SoundCloud. You can also listen on Spotify, Apple Podcasts, Stitcher, Pocket Casts or wherever you listen to podcasts. The Biden administration this week proposed a series of changes aimed at boosting insurance enrollment under the Affordable Care Act, undoing changes made by the Trump administration […]

Categories
Uncategorized

KHN’s ‘What the Health?’: The ACA Lives

Can’t see the audio player? Click here to listen on SoundCloud. You can also listen on Spotify, Apple Podcasts, Stitcher, Pocket Casts or wherever you listen to podcasts. For the third time in nine years, the Affordable Care Act has survived a constitutional challenge at the Supreme Court. In a 7-2 decision, the court ruled […]

Categories
Uncategorized

Journalists Discuss New Alzheimer’s Drug, Women’s Alcohol Use, the Hip-Hop and Opioids Link

KHN chief Washington correspondent Julie Rovner discussed the FDA’s approval of a new drug for Alzheimer’s disease on WAMU’s “1A” on Wednesday. KHN correspondent Aneri Pattani discussed the increase in alcohol use and misuse by young women on NPR’s “All Things Considered” on Wednesday. KHN freelancer Harris Meyer discussed the FDA’s approval of a new […]

Categories
Uncategorized

FDA Weighs Approval of a Lucrative Alzheimer’s Drug, but Benefits Are Iffy

The Food and Drug Administration’s decision next week whether to approve the first treatment for Alzheimer’s disease highlights a deep division over the drug’s benefits as well as criticism about the integrity of the FDA approval process. The agency said it will decide by June 7 the fate of Biogen’s drug aducanumab, despite a near-unanimous […]